ARQT vs. ADMA
Compare and contrast key facts about Arcutis Biotherapeutics, Inc. (ARQT) and ADMA Biologics, Inc. (ADMA).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ARQT or ADMA.
Correlation
The correlation between ARQT and ADMA is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
ARQT vs. ADMA - Performance Comparison
Key characteristics
ARQT:
0.95
ADMA:
2.94
ARQT:
1.78
ADMA:
3.65
ARQT:
1.20
ADMA:
1.48
ARQT:
0.87
ADMA:
4.58
ARQT:
5.30
ADMA:
13.73
ARQT:
13.20%
ADMA:
15.07%
ARQT:
73.21%
ADMA:
71.91%
ARQT:
-95.02%
ADMA:
-91.28%
ARQT:
-63.45%
ADMA:
-13.50%
Fundamentals
ARQT:
$1.82B
ADMA:
$5.61B
ARQT:
-$1.16
ADMA:
$0.81
ARQT:
9.35
ADMA:
13.26
ARQT:
11.66
ADMA:
16.08
ARQT:
$146.97M
ADMA:
$344.58M
ARQT:
$131.10M
ADMA:
$180.30M
ARQT:
-$82.41M
ADMA:
$123.41M
Returns By Period
In the year-to-date period, ARQT achieves a -2.98% return, which is significantly lower than ADMA's 23.62% return.
ARQT
-2.98%
1.69%
29.95%
69.15%
-11.25%
N/A
ADMA
23.62%
18.70%
7.51%
209.04%
54.63%
10.56%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
ARQT vs. ADMA — Risk-Adjusted Performance Rank
ARQT
ADMA
ARQT vs. ADMA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
ARQT vs. ADMA - Dividend Comparison
Neither ARQT nor ADMA has paid dividends to shareholders.
Drawdowns
ARQT vs. ADMA - Drawdown Comparison
The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum ADMA drawdown of -91.28%. Use the drawdown chart below to compare losses from any high point for ARQT and ADMA. For additional features, visit the drawdowns tool.
Volatility
ARQT vs. ADMA - Volatility Comparison
The current volatility for Arcutis Biotherapeutics, Inc. (ARQT) is 19.14%, while ADMA Biologics, Inc. (ADMA) has a volatility of 25.35%. This indicates that ARQT experiences smaller price fluctuations and is considered to be less risky than ADMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
ARQT vs. ADMA - Financials Comparison
This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and ADMA Biologics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ARQT vs. ADMA - Profitability Comparison
ARQT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a gross profit of 64.46M and revenue of 71.36M. Therefore, the gross margin over that period was 90.3%.
ADMA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported a gross profit of 63.33M and revenue of 117.55M. Therefore, the gross margin over that period was 53.9%.
ARQT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported an operating income of -7.63M and revenue of 71.36M, resulting in an operating margin of -10.7%.
ADMA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported an operating income of 38.32M and revenue of 117.55M, resulting in an operating margin of 32.6%.
ARQT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a net income of -10.79M and revenue of 71.36M, resulting in a net margin of -15.1%.
ADMA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported a net income of 111.90M and revenue of 117.55M, resulting in a net margin of 95.2%.